Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells $16,734.90 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 3,678 shares of the company’s stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $4.55, for a total value of $16,734.90. Following the completion of the sale, the chief financial officer now owns 89,868 shares of the company’s stock, valued at approximately $408,899.40. The trade was a 3.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Molly Henderson also recently made the following trade(s):

• On Tuesday, January 21st, Molly Henderson sold 6,583 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $6.59, for a total value of $43,381.97.

Phathom Pharmaceuticals Stock Down 12.7 %

NASDAQ PHAT traded down $0.62 on Tuesday, reaching $4.25. The company had a trading volume of 937,718 shares, compared to its average volume of 1,005,362. The stock has a market capitalization of $295.96 million, a PE ratio of -0.75 and a beta of 0.35. The firm’s 50 day moving average price is $5.66 and its 200 day moving average price is $9.51. Phathom Pharmaceuticals, Inc. has a 12 month low of $4.07 and a 12 month high of $19.71.

Wall Street Analysts Forecast Growth

PHAT has been the subject of a number of recent analyst reports. The Goldman Sachs Group dropped their price target on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “neutral” rating for the company in a research report on Monday, March 10th. Craig Hallum reaffirmed a “buy” rating on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $22.17.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wasatch Advisors LP lifted its position in Phathom Pharmaceuticals by 531.3% during the fourth quarter. Wasatch Advisors LP now owns 1,558,928 shares of the company’s stock valued at $12,658,000 after purchasing an additional 1,311,986 shares during the last quarter. FMR LLC boosted its stake in shares of Phathom Pharmaceuticals by 49,000.7% during the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after purchasing an additional 1,301,458 shares during the period. Jennison Associates LLC grew its stake in Phathom Pharmaceuticals by 20.4% in the 4th quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock worth $57,348,000 after acquiring an additional 1,196,118 shares in the last quarter. Tang Capital Management LLC bought a new position in Phathom Pharmaceuticals in the fourth quarter worth approximately $4,060,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Phathom Pharmaceuticals in the fourth quarter valued at about $3,701,000. 99.01% of the stock is owned by institutional investors.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.